
Melanoma: Genetic Testing and Its Role in Cutaneous Malignant Susceptibility
CDKN2A and BAP1 mutations mark people more likely to develop cutaneous malignant melanoma, guiding skin checks, UV precautions and choice of targeted therapy.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

CDKN2A and BAP1 mutations mark people more likely to develop cutaneous malignant melanoma, guiding skin checks, UV precautions and choice of targeted therapy.

Alazami type brings microcephaly, growth restriction, distinctive facial features and intellectual disability in early childhood; testing identifies the mutation.

Severe antenatal microencephaly and brain structural abnormalities follow ZNF335 deficiency. Testing confirms the cause and clarifies recessive inheritance.

Variants in WDR62 disrupt brain development and produce a head circumference well below average. Whole-exome sequencing can name the change behind Microcephaly 11.

Vision in MIC9 ranges from mildly impaired to absent; PAX6 variants and parental mosaicism explain why relatives differ, and testing can detect both.

Whole-exome sequencing uncovered a novel UQCRB variant in this nuclear type 2 deficiency, which is reported with hypoglycemia, lactic acidosis and muscle weakness.

Impaired energy production brings recurrent hypoglycemia and lactic acidosis in Complex III Deficiency Nuclear Type 3, where a novel UQCRB variant was identified.

Recurrent hypoglycemia and lactic acidosis in a child can point to Complex III Deficiency Nuclear Type 4, linked to UQCRB and other nuclear gene mutations.